Search
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigationalSipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting.
Isavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalIt is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026]. … has a potential for nephrotoxicity [A32029].
Quercetin
go.drugbank.com/drugs/DB04216InvestigationalQuercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.
Categories: Compounds used in a research, industrial, or household settingEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalepisodes in patients with hemophilia A. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalPalifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Metyrosine
go.drugbank.com/drugs/DB00765ApprovedInvestigationalAn inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.
Aluminum oxide
go.drugbank.com/drugs/DB11342ApprovedWithdrawnIt is considered an indirect additive used in food contact substances by the FDA. … Aluminum oxide has a chemical formula Al2O3. It is amphoteric in nature, and is used in various chemical, industrial and commercial applications.
Segatroxaban
go.drugbank.com/drugs/DB21678ExperimentalSegatroxaban has a monoisotopic molecular weight of 567.14 Da. … Segatroxaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Segatroxaban is a blood coagulation factor XA inhibitor, antithrombotic.
PN0621
go.drugbank.com/drugs/DB05218ExperimentalPN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.
ATHX-105
go.drugbank.com/drugs/DB06008InvestigationalATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.